Lifestyle and Subsequent Malignant Neoplasms in Childhood Cancer Survivors: A Report from the St. Jude Lifetime Cohort Study
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Population
2.2. Self-Reported Exposures
2.3. Objectively Assessed Exposures
2.4. Childhood Cancer Treatment
2.5. Outcomes
3. Statistical Analysis
4. Results
4.1. Baseline Characteristics
4.2. Incidence and Risk Factors for SMNs
4.3. Associations between Lifestyle and SMNs
5. Discussion
6. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Ehrhardt, M.J.; Krull, K.R.; Bhakta, N.; Liu, Q.; Yasui, Y.; Robison, L.L.; Hudson, M.M. Improving quality and quantity of life for childhood cancer survivors globally in the twenty-first century. Nat. Rev. Clin. Oncol. 2023, 20, 678–696. [Google Scholar] [CrossRef] [PubMed]
- Turcotte, L.M.; Neglia, J.P.; Reulen, R.C.; Ronckers, C.M.; van Leeuwen, F.E.; Morton, L.M.; Hodgson, D.C.; Yasui, Y.; Oeffinger, K.C.; Henderson, T.O. Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review. J. Clin. Oncol. 2018, 36, 2145–2152. [Google Scholar] [CrossRef] [PubMed]
- Ness, K.K.; Leisenring, W.M.; Huang, S.; Hudson, M.M.; Gurney, J.G.; Whelan, K.; Hobbie, W.L.; Armstrong, G.T.; Robison, L.L.; Oeffinger, K.C. Predictors of inactive lifestyle among adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer 2009, 115, 1984–1994. [Google Scholar] [CrossRef] [PubMed]
- Ness, K.K.; Plana, J.C.; Joshi, V.M.; Luepker, R.V.; Durand, J.B.; Green, D.M.; Partin, R.E.; Santucci, A.K.; Howell, R.M.; Srivastava, D.K.; et al. Exercise Intolerance, Mortality, and Organ System Impairment in Adult Survivors of Childhood Cancer. J. Clin. Oncol. 2020, 38, 29–42. [Google Scholar] [CrossRef] [PubMed]
- U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General; U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: Atlanta, GA, USA, 2014.
- Secretan, B.; Straif, K.; Baan, R.; Grosse, Y.; El Ghissassi, F.; Bouvard, V.; Benbrahim-Tallaa, L.; Guha, N.; Freeman, C.; Galichet, L.; et al. A review of human carcinogens—Part E: Tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009, 10, 1033–1034. [Google Scholar] [CrossRef] [PubMed]
- Lauby-Secretan, B.; Scoccianti, C.; Loomis, D.; Grosse, Y.; Bianchini, F.; Straif, K.; International Agency for Research on Cancer Handbook Working Group. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N. Engl. J. Med. 2016, 375, 794–798. [Google Scholar] [CrossRef] [PubMed]
- Furer, A.; Afek, A.; Sommer, A.; Keinan-Boker, L.; Derazne, E.; Levi, Z.; Tzur, D.; Tiosano, S.; Shina, A.; Glick, Y.; et al. Adolescent obesity and midlife cancer risk: A population-based cohort study of 2.3 million adolescents in Israel. Lancet Diabetes Endocrinol. 2020, 8, 216–225. [Google Scholar] [CrossRef] [PubMed]
- Onerup, A.; Mehlig, K.; Af Geijerstam, A.; Ekblom Bak, E.; Kuhn, H.G.; Lissner, L.; Rosengren, A.; Börjesson, M.; Åberg, M. Associations between body mass index in youth and site-specific cancer in men—A cohort study with register linkage. Obesity 2023. ahead of print. [Google Scholar]
- Bull, F.C.; Al-Ansari, S.S.; Biddle, S.; Borodulin, K.; Buman, M.P.; Cardon, G.; Carty, C.; Chaput, J.P.; Chastin, S.; Chou, R.; et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br. J. Sports Med. 2020, 54, 1451–1462. [Google Scholar] [CrossRef] [PubMed]
- Onerup, A.; Mehlig, K.; Af Geijerstam, A.; Ekblom Bak, E.; Kuhn, H.G.; Lissner, L.; Aberg, M.; Borjesson, M. Associations between cardiorespiratory fitness in youth and the incidence of site-specific cancer in men: A cohort study with register linkage. Br. J. Sports Med. 2023, 57, 1248–1256. [Google Scholar] [CrossRef] [PubMed]
- Howell, C.R.; Bjornard, K.L.; Ness, K.K.; Alberts, N.; Armstrong, G.T.; Bhakta, N.; Brinkman, T.; Caron, E.; Chemaitilly, W.; Green, D.M.; et al. Cohort Profile: The St. Jude Lifetime Cohort Study (SJLIFE) for paediatric cancer survivors. Int. J. Epidemiol. 2021, 50, 39–49. [Google Scholar] [CrossRef] [PubMed]
- Hudson, M.M.; Ehrhardt, M.J.; Bhakta, N.; Baassiri, M.; Eissa, H.; Chemaitilly, W.; Green, D.M.; Mulrooney, D.A.; Armstrong, G.T.; Brinkman, T.M.; et al. Approach for Classification and Severity Grading of Long-term and Late-Onset Health Events among Childhood Cancer Survivors in the St. Jude Lifetime Cohort. Cancer Epidemiol. Biomark. Prev. 2017, 26, 666–674. [Google Scholar] [CrossRef] [PubMed]
- Mizrahi, D.; Fardell, J.E.; Cohn, R.J.; Partin, R.E.; Howell, C.R.; Hudson, M.M.; Robison, L.L.; Ness, K.K.; McBride, J.; Field, P.; et al. The 6-minute walk test is a good predictor of cardiorespiratory fitness in childhood cancer survivors when access to comprehensive testing is limited. Int. J. Cancer 2020, 147, 847–855. [Google Scholar] [CrossRef] [PubMed]
- Fitch, A.K.; Bays, H.E. Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obes. Pillars 2022, 1, 100004. [Google Scholar] [CrossRef] [PubMed]
- Dixon, S.B.; Liu, Q.; Chow, E.J.; Oeffinger, K.C.; Nathan, P.C.; Howell, R.M.; Leisenring, W.M.; Ehrhardt, M.J.; Ness, K.K.; Krull, K.R.; et al. Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study cohort. Lancet 2023, 401, 1447–1457. [Google Scholar] [CrossRef] [PubMed]
- Feijen, E.A.M.; Leisenring, W.M.; Stratton, K.L.; Ness, K.K.; van der Pal, H.J.H.; van Dalen, E.C.; Armstrong, G.T.; Aune, G.J.; Green, D.M.; Hudson, M.M.; et al. Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity. JAMA Oncol. 2019, 5, 864–871. [Google Scholar] [CrossRef] [PubMed]
- Wang, Z.; Wilson, C.L.; Easton, J.; Thrasher, A.; Mulder, H.; Liu, Q.; Hedges, D.J.; Wang, S.; Rusch, M.C.; Edmonson, M.N.; et al. Genetic Risk for Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer. J. Clin. Oncol. 2018, 36, 2078–2087. [Google Scholar] [CrossRef] [PubMed]
- Fritz, A.G. International Classification of Diseases for Oncology: ICD-O, 3rd ed.; World Health Organization: Geneva, Switzerland, 2000; Volume VII, 240p.
- Moke, D.J.; Hamilton, A.S.; Chehab, L.; Deapen, D.; Freyer, D.R. Obesity and Risk for Second Malignant Neoplasms in Childhood Cancer Survivors: A Case-Control Study Utilizing the California Cancer Registry. Cancer Epidemiol. Biomark. Prev. 2019, 28, 1612–1620. [Google Scholar] [CrossRef] [PubMed]
- Celind, J.; Bygdell, M.; Martikainen, J.; Ohlsson, C.; Kindblom, J.M. Childhood overweight and risk of obesity-related adult cancer in men. Cancer Commun. 2022, 42, 576–579. [Google Scholar] [CrossRef] [PubMed]
Developed Any SMN | No SMN | Total | P between Groups | Developed Breast Cancer | Developed Thyroid Cancer | Developed Gastrointestinal Cancer | |
---|---|---|---|---|---|---|---|
Number of participants | 178 | 3894 | 4072 | 38 | 41 | 28 | |
Sex, female, n (%) | 105 (59%) | 1820 (47%) | 1925 (47%) | 0.001 | 36 (95%) | 22 (54%) | 18 (64%) |
Age at baseline, years, mean (sd) | 36.3 (8.9) | 29.8 (8.3) | 30.1 (8.5) | <0.001 | 38.3 (7.0) | 34.4 (6.6) | 36.0 (8.9) |
Years of follow-up, mean (sd) | 5.3 (2.9) | 7.1 (3.3) | 7.0 (3.3) | <0.001 | 6.4 (3.4) | 4.8 (2.6) | 5.8 (3.1) |
Race/ethnicity, n (%) | 0.075 | ||||||
Non-hispanic white | 156 (88%) | 3101 (80%) | 3257 (80%) | 33 (87%) | 38 (93%) | 25 (89%) | |
Non-hispanic black | 18 (10%) | 605 (16%) | 623 (15%) | 3 (7.9%) | 2 (4.9%) | 2 (7.1%) | |
Hispanic | 3 (1.7%) | 111 (2.9%) | 114 (2.8%) | 2 (5.3%) | 1 (2.4%) | 1 (3.6%) | |
Other | 1 (0.6%) | 77 (2.0%) | 78 (1.9%) | 0 | 0 | 0 | |
Educational attainment, n (%) | 0.046 | ||||||
<High school, high school graduate or ged | 43 (25%) | 1150 (32%) | 1193 (31%) | 7 (18%) | 6 (15%) | 10 (36%) | |
Training after high school or some college | 60 (35%) | 1316 (36%) | 1376 (36%) | 12 (32%) | 17 (44%) | 8 (29%) | |
College graduate or postgraduate | 70 (40%) | 1164 (32%) | 1234 (32%) | 19 (50%) | 16 (41%) | 10 (36%) | |
Missing | 5 | 264 | 269 | 0 | 2 | 0 | |
Household income per year, n (%) | 0.31 | ||||||
<USD 20,000 | 56 (37%) | 1336 (44%) | 1392 (43%) | 9 (27%) | 14 (42%) | 12 (48%) | |
USD 20,000–USD 59,999 | 54 (36%) | 999 (33%) | 1053 (33%) | 13 (39%) | 11 (33%) | 6 (24%) | |
≥USD 60,000 | 40 (27%) | 723 (24%) | 763 (24%) | 11 (33%) | 8 (24%) | 7 (28%) | |
Missing | 28 | 836 | 864 | 5 | 8 | 3 | |
Body mass index, mean (sd) | 28.9 (7.4) | 28.2 (7.2) | 28.2 (7.2) | 0.10 | 28.8 (8.1) | 29.1 (7.0) | 28.6 (7.6) |
Underweight (<18.5 kg/m2), n (%) | 7 (3.9%) | 143 (3.7%) | 150 (3.7%) | 3 (7.9%) | 2 (4.9%) | 0 | |
Normal weight (18.5/24.9 kg/m2), n (%) | 50 (28%) | 1355 (35%) | 1405 (34%) | 10 (26%) | 9 (22%) | 12 (43%) | |
Overweight (25/29.9 kg/m2), n (%) | 63 (35%) | 1069 (27%) | 1132 (28%) | 13 (34%) | 18 (44%) | 8 (29%) | |
Obesity (≥30 kg/m2), n (%) | 58 (33%) | 1326 (34%) | 1384 (34%) | 12 (32%) | 12 (29%) | 8 (29%) | |
Body fat percentage,%, mean (sd) a | 33 (9) | 32 (9) | 32 (9) | 0.45 | 35 (7) | 33 (9) | 31 (9) |
Missing | 79 | 733 | 812 | 21 | 16 | 10 | |
Non-obese, n (%) | 23 (23%) | 886 (28%) | 909 (28%) | 3 (18%) | 4 (16%) | 7 (39%) | |
Pre-obese, n (%) | 27 (27%) | 722 (23%) | 749 (23%) | 6 (35%) | 9 (36%) | 4 (22%) | |
Obese, n (%) | 49 (49%) | 1553 (49%) | 1602 (49%) | 8 (47%) | 12 (48%) | 7 (39%) | |
6 min walk test, meters walked, mean (sd) | 564 (100) | 555 (104) | 556 (104) | 0.13 | 561 (87) | 588 (101) | 557 (86) |
Missing | 7 | 156 | 163 | 0 | 0 | 2 | |
Grip strength, kg, mean (sd) | 37.7 (12.4) | 39.3 (13.3) | 39.3 (13.3) | 0.071 | 30.0 (5.8) | 40.0 (14.8) | 37.2 (13.3) |
Missing | 0 | 8 | 8 | 0 | 0 | 0 | |
Knee extension, nm/kg, mean (sd) | 133 (48) | 142 (56) | 141 (56) | 0.069 | 116.8 (35.5) | 139.8 (53.0) | 133.5 (48.2) |
Missing | 17 | 443 | 460 | 2 | 1 | 3 | |
Self-reported physical activity, meth/wk, median (iqr) | 5.8 (0.5–18.4) | 9.0 (0.0–24.0) | 9.0 (0.0–24.0) | 0.11 | 13.0 (1.3–21.8) | 4.3 (0.4–12.0) | 9.0 (3.0–26.3) |
Missing | 10 | 229 | 239 | 3 | 1 | 1 | |
Smoking history, n (%) | 0.046 | ||||||
Never | 107 (63%) | 2677 (71%) | 2784 (71%) | 25 (69%) | 30 (73%) | 18 (67%) | |
Past | 28 (16%) | 436 (12%) | 464 (12%) | 7 (19%) | 5 (12%) | 3 (11%) | |
Current | 35 (21%) | 634 (17%) | 669 (17%) | 4 (11%) | 6 (15%) | 6 (22%) | |
Missing | 8 | 147 | 155 | 0 | 1 | ||
Heavy/risky drinking b, n (%) | 65 (38%) | 1370 (37%) | 1435 (37%) | 0.75 | 14 (40%) | 13 (32%) | 10 (37%) |
Missing | 9 | 215 | 224 | 3 | 1 | 1 | |
Healthy lifestyle score c, n (%) | 0.086 | ||||||
Unhealthy | 98 (59%) | 1843 (51%) | 1941 (51%) | 15 (43%) | 22 (55%) | 16 (59%) | |
Moderate | 54 (32%) | 1275 (35%) | 1329 (35%) | 18 (51%) | 14 (35%) | 6 (22%) | |
Healthy | 15 (9.0%) | 497 (14%) | 512 (14%) | 2 (5.7%) | 4 (10%) | 5 (19%) | |
Decade of primary cancer diagnosis, n (%) | <0.001 | ||||||
1960–1970 | 9 (5.1%) | 110 (2.8%) | 119 (2.9%) | 2 (5.3%) | 0 | 2 (7.1%) | |
1971–1980 | 49 (28%) | 576 (15%) | 625 (15%) | 8 (21%) | 8 (20%) | 10 (36%) | |
1981–1990 | 77 (43%) | 1015 (26%) | 1092 (27%) | 19 (50%) | 19 (46%) | 11 (39%) | |
1991–2000 | 37 (21%) | 1320 (34%) | 1357 (33%) | 9 (24%) | 11 (27%) | 4 (14%) | |
2001– | 6 (3.4%) | 873 (23%) | 879 (22%) | 0 | 3 (7.3%) | 1 (3.6%) | |
Primary childhood cancer diagnosis, n (%) | <0.001 | ||||||
Acute lymphoblastic leukemia | 42 (24%) | 1164 (30%) | 1206 (30%) | 11 (29%) | 10 (24%) | 5 (18%) | |
Acute myeloblastic leukemia/other leukemia | 7 (3.9%) | 153 (3.9%) | 160 (3.9%) | 1 (2.6%) | 2 (4.9%) | 2 (7.1%) | |
Non-hodgkin lymphoma | 10 (5.6%) | 268 (6.9%) | 278 (6.8%) | 2 (5.3%) | 1 (2.4%) | 3 (11%) | |
Hodgkin lymphoma | 58 (33%) | 416 (11%) | 474 (12%) | 19 (50%) | 19 (46%) | 6 (21%) | |
Central nervous system tumor | 10 (5.6%) | 543 (14%) | 553 (14%) | 1 (2.6%) | 2 (4.9%) | 1 (3.6%) | |
Neuroblastoma | 11 (6.2%) | 159 (4.1%) | 170 (4.2%) | 1 (2.6%) | 1 (2.4%) | 2 (7.1%) | |
Wilms tumor | 6 (3.4%) | 232 (6.0%) | 238 (5.8%) | 0 | 0 | 4 (14%) | |
Soft tissue sarcoma | 3 (1.7%) | 122 (3.1%) | 125 (3.1%) | 0 | 0 | 1 (3.6%) | |
Osteosarcoma | 5 (2.8%) | 161 (4.1%) | 166 (4.1%) | 0 | 0 | 2 (7.1%) | |
Ewing sarcoma family | 8 (4.5%) | 114 (2.9%) | 122 (3.0%) | 3 (7.9%) | 1 (2.4%) | 0 | |
Retinoblastoma | 4 (2.2%) | 127 (3.3%) | 131 (3.2%) | 0 | 1 (2.4%) | 0 | |
Other | 14 (7.9%) | 435 (11%) | 449 (11%) | 0 | 4 (9.8%) | 2 (7.1%) | |
Age at primary cancer diagnosis, years, mean (sd) | 10.9 (6.1) | 8.6 (5.6) | 8.7 (5.7) | <0.001 | 13.3 (4.8) | 12.1 (5.8) | 8.5 (6.4) |
Received radiation treatment, n (%) | 139 (78%) | 2078 (53%) | 2217 (54%) | <0.001 | 30 (79%) | 36 (88%) | 18 (64%) |
Received alkylating agents, n (%) | 125 (70%) | 2234 (57%) | 2359 (58%) | 0.002 | 26 (68%) | 28 (68%) | 20 (71%) |
Received anthracyclines, n (%) | 104 (58%) | 2240 (58%) | 2344 (58%) | 0.92 | 22 (58%) | 28 (68%) | 17 (61%) |
Received platinum, n (%) | 21 (12%) | 548 (14%) | 569 (14%) | 0.36 | 2 (5.3%) | 2 (4.9%) | 5 (18%) |
Received epipodophyllotoxins, n (%) | 58 (33%) | 1405 (36%) | 1463 (36%) | 0.23 | 10 (26%) | 19 (46%) | 8 (29%) |
Hematopoietic stem cell transplant, n (%) | 17 (10%) | 308 (8%) | 325 (8%) | 0.43 | 2 (5.3%) | 6 (15%) | 3 (11%) |
Any SMN | Subsequent Breast Cancer | ||||
---|---|---|---|---|---|
Univariate Analyses | Multivariable Model Incl. Treatment 1 | Multivariable Model Incl. Diagnosis 2 | Univariate Analyses | Treatment Model 1 | |
RR (95% CI) | RR (95% CI) | RR (95% CI) | RR (95% CI) | RR (95% CI) | |
Body mass index (bmi) | |||||
Overweight (bmi ≥ 25–29.9) | 1.5 (1.0–2.2) | 1.3 (0.9–1.9) | 1.3 (0.9–2.0) | 1.5 (0.7–3.5) | NA |
Obesity (bmi ≥ 30) | 1.1 (0.7–1.6) | 0.9 (0.6–1.4) | 1.0 (0.7–1.5) | 1.1 (0.5–2.6) | NA |
Body fat percentage a | |||||
Pre-obesity vs. Normal | 1.4 (0.8–2.4) | 1.1 (0.6–1.9) | 1.2 (0.7–2.1) | 2.4 (0.6–9.6) | 1.8 (0.4–7.2) |
Obesity vs. Normal | 1.2 (0.7–1.9) | 0.7 (0.4–1.2) | 0.9 (0.5–1.5) | 1.6 (0.4–6.0) | 0.7 (0.2–2.6) |
Self-reported physical activity | |||||
3–6 vs. 0–3 meth/wk | 0.8 (0.5–1.3) | 1.4 (0.8–2.3) | 0.9 (0.6–1.4) | 1.9 (0.8–4.3) | NA |
≥6 vs. 0–3 meth/wk | 0.7 (0.5–1.0) | 1.1 (0.8–1.5) | 0.8 (0.6–1.2) | 1.1 (0.5–2.4) | NA |
Cardiorespiratory fitness b | |||||
Quartile 4 vs. 1 | 1.1 (0.7–1.7) | 1.4 (0.8–2.2) | 1.0 (0.6–1.6) | 0.8 (0.3–2.1) | NA |
Quartile 3 vs. 1 | 1.3 (0.9–2.1) | 1.7 (1.0–2.6) | 1.3 (0.8–2.1) | 1.4 (0.6–3.3) | NA |
Quartile 2 vs. 1 | 1.0 (0.6–1.8) | 1.2 (0.7–1.9) | 1.0 (0.6–1.6) | 0.9 (0.3–2.3) | NA |
Grip strength | |||||
High vs. Low | 0.7 (0.5–1.1) | 0.9 (0.5–1.6) | 1.2 (0.7–2.1) | 0.1 (0.04–0.3) | 0.9 (0.4–1.8) |
Moderate vs. Low | 1.0 (0.7–1.5) | 0.9 (0.6–1.3) | 1.0 (0.7–1.5) | 0.7 (0.4–1.5) | 1.1 (0.3–4.4) |
Knee extension | |||||
High vs. Low | 0.7 (0.5–1.1) | 1.1 (0.7–1.8) | 1.0 (0.6–1.6) | 0.4 (0.2–1.03) | 2.0 (0.8–5.4) |
Moderate vs. Low | 1.1 (0.7–1.6) | 1.2 (0.8–1.8) | 1.1 (0.7–1.7) | 1.6 (0.8–3.6) | 2.2 (1.0–5.0) |
Never smoker | 0.8 (0.6–1.1) | 0.9 (0.7–1.3) | 0.9 (0.6–1.3) | 1.1 (0.5–2.2) | NA |
Absence of risky drinking c | 1.0 (0.7–1.3) | 0.7 (0.5–1.1) | 0.9 (0.6–1.2) | 0.9 (0.5–1.8) | NA |
Healthy lifestyle score d | |||||
Moderate | 0.9 (0.6–1.2) | 0.9 (0.7–1.3) | 0.9 (0.7–1.3) | 1.9 (1.0–3.8) | NA |
Healthy | 0.6 (0.4–1.1) | 0.9 (0.6–1.4) | 0.8 (0.4–1.3) | 0.5 (0.1–2.4) | NA |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Onerup, A.; Mirzaei, S.; Bhatia, S.; Åberg, M.; Ware, M.E.; Joffe, L.; Turcotte, L.M.; Goodenough, C.G.; Sapkota, Y.; Dixon, S.B.; et al. Lifestyle and Subsequent Malignant Neoplasms in Childhood Cancer Survivors: A Report from the St. Jude Lifetime Cohort Study. Cancers 2024, 16, 864. https://doi.org/10.3390/cancers16050864
Onerup A, Mirzaei S, Bhatia S, Åberg M, Ware ME, Joffe L, Turcotte LM, Goodenough CG, Sapkota Y, Dixon SB, et al. Lifestyle and Subsequent Malignant Neoplasms in Childhood Cancer Survivors: A Report from the St. Jude Lifetime Cohort Study. Cancers. 2024; 16(5):864. https://doi.org/10.3390/cancers16050864
Chicago/Turabian StyleOnerup, Aron, Sedigheh Mirzaei, Shalini Bhatia, Maria Åberg, Megan E. Ware, Lenat Joffe, Lucie M. Turcotte, Chelsea G. Goodenough, Yadav Sapkota, Stephanie B. Dixon, and et al. 2024. "Lifestyle and Subsequent Malignant Neoplasms in Childhood Cancer Survivors: A Report from the St. Jude Lifetime Cohort Study" Cancers 16, no. 5: 864. https://doi.org/10.3390/cancers16050864
APA StyleOnerup, A., Mirzaei, S., Bhatia, S., Åberg, M., Ware, M. E., Joffe, L., Turcotte, L. M., Goodenough, C. G., Sapkota, Y., Dixon, S. B., Wogksch, M. D., Ehrhardt, M. J., Armstrong, G. T., Hudson, M. M., & Ness, K. K. (2024). Lifestyle and Subsequent Malignant Neoplasms in Childhood Cancer Survivors: A Report from the St. Jude Lifetime Cohort Study. Cancers, 16(5), 864. https://doi.org/10.3390/cancers16050864